Results 101 to 110 of about 183,492 (354)
Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update [PDF]
, 2019 Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease (FLD), is a major public health problem. It is considered to be the hepatic manifestation of the metabolic syndrome.
Breaban, Iulia +10 more
core +1 more source
Animal models of NASH: getting both pathology and metabolic context right [PDF]
, 2015 Non-alcoholic fatty liver disease (NAFLD) is the most common cause of referral to liver clinics, and its progressive form, non-alcoholic steatohepatitis (NASH), can lead to cirrhosis and end-stage liver disease.
Larter, Claire Z., Yeh, Matthew M.
core +1 more source
Advanced Healthcare Materials, EarlyView.A human cell‐based microphysiological system integrates engineered muscle tissues with an inflamed adipose–macrophage niche to model obese microenvironment‐induced muscle dysfunction. Muscle contraction is quantified by pillar deflection coupled with computational stiffness estimation. Secretome and transcriptomic profiling reveal inflammation‐mediated
Seunggyu Kim +16 more
wiley +1 more source
Vitamin D to reduce liver fibrosis in non-alcoholic fatty liver disease [PDF]
, 2017 BACKGROUND: As the prevalence of metabolic risk factors in the American population has increased over time, so too has the diagnoses of non-alcoholic fatty liver disease (NAFLD).
Fox, Ryan
core
Relationship between adipose tissue dysfunction, Vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease [PDF]
, 2017 Non-alcoholic fatty liver disease ( NAFLD) is the most common chronic liver disease worldwide. Its pathogenesis is complex and not yet fully understood.
BARCHETTA, ILARIA +7 more
core +1 more source
Advanced Healthcare Materials, EarlyView.Recent advances in diagnostics have accelerated the development of miniaturized wearable technologies for the continuous monitoring of diseases. This paradigm is shifting healthcare away from invasive, centralized blood tests toward decentralized monitoring, using alternative body biofluids.
Lanka Tata Rao +2 more
wiley +1 more source
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets [PDF]
, 2013 Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in children. NAFLD has emerged to be extremely prevalent, and predicted by obesity and male gender.
Giorgio V +3 more
core +1 more source
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease [PDF]
, 2022 Karim Seif El Dahan +2 more
openalex +1 more source
Iron and non-alcoholic fatty liver disease
World Journal of Gastroenterology, 2016 The mechanisms that promote liver injury in non-alcoholic fatty liver disease (NAFLD) are yet to be thoroughly elucidated. As such, effective treatment strategies are lacking and novel therapeutic targets are required. Iron has been widely implicated in the pathogenesis of NAFLD and represents a potential target for treatment.
Britton, Laurence +2 more
openaire +3 more sources
Treatment of Non-Alcoholic Fatty Liver Disease [PDF]
Digestive Diseases, 2016 Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions from steatosis to cirrhosis and hepatocellular carcinoma. Steatosis is a benign reversible condition, which does not need treatment. Cirrhosis and hepatocellular carcinoma are the end stages of any chronic liver disease and do not have etiology-specific treatments.
Scherer, Antonia, Dufour, Jean-François
openaire +3 more sources